These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3250051)

  • 1. The "forgotten" amino acid pyroglutamate.
    Moret C; Briley M
    Trends Pharmacol Sci; 1988 Aug; 9(8):278-9. PubMed ID: 3250051
    [No Abstract]   [Full Text] [Related]  

  • 2. Isolation of pyroglutamic acid from hypothalamic tissue and significance of its inhibition of prolactin release.
    Lam YK; Knudsen R; Folkers K
    Biochem Biophys Res Commun; 1978 Mar; 81(2):680-3. PubMed ID: 666779
    [No Abstract]   [Full Text] [Related]  

  • 3. Pyroglutamic acid. Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal.
    Abraham GN; Podell DN
    Mol Cell Biochem; 1981 Aug; 38 Spec No(Pt 1):181-90. PubMed ID: 6117006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of arginine pyroglutamate on pentobarbital anesthesia].
    Provenzano PM; Brucato A; Gianguzza eS
    Boll Soc Ital Biol Sper; 1974 Nov; 50(21):1753-7. PubMed ID: 4462759
    [No Abstract]   [Full Text] [Related]  

  • 5. Cell-free synthesis of amino-terminal L-pyroglutamic acid.
    Jones GH
    Biochemistry; 1974 Feb; 13(5):855-60. PubMed ID: 4813368
    [No Abstract]   [Full Text] [Related]  

  • 6. Pyroglutamic aciduria: rate of formation and degradation of pyroglutamate.
    Eldjarn L; Jellum E; Stokke O
    Clin Chim Acta; 1973 Dec; 49(3):311-23. PubMed ID: 4776475
    [No Abstract]   [Full Text] [Related]  

  • 7. A CONVENIENT PROCEDURE FOR THE DETERMINATION OF PYRROLIDONECARBOXYLIC ACID AND RELATED COMPOUNDS.
    POLGAR P; MEISTER A
    Anal Biochem; 1965 Aug; 12():338-43. PubMed ID: 14340027
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and preliminary evaluation of trans-3,4-conformationally-restricted glutamate and pyroglutamate analogues as novel EAAT2 inhibitors.
    Denton T; Seib T; Bridges R; Thompson C
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3209-13. PubMed ID: 12372536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyroglutamate kinetics and neurotoxicity studies in mice.
    Caccia S; Ghezzi P; Garattini S; Salmona M; Takasaki Y; Torii K
    Toxicol Lett; 1983 May; 16(3-4):225-9. PubMed ID: 6134358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THE METABOLIC FORMATION OF PYRROLIDONECARBOXYLIC ACID FROM L-GLUTAMIC ACID IN RAT LIVER.
    NIWAGUCHI T; MOTOHASHI N; STRECKER HJ
    Biochim Biophys Acta; 1964 Mar; 82():635-6. PubMed ID: 14148839
    [No Abstract]   [Full Text] [Related]  

  • 11. gamma-Amino-eta-butyric, aspartic, glutamic and pyrrolidonecarboxylic acid; their determination and occurrence in grass during conservation.
    MACPHERSON HT; SLATER JS
    Biochem J; 1959 Apr; 71(4):654-60. PubMed ID: 13651112
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of pyroglutamic acid on corticostriatal glutamatergic transmission.
    Dusticier N; Kerkerian L; Errami M; Nieoullon A
    Neuropharmacology; 1985 Sep; 24(9):903-8. PubMed ID: 2997655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A technique for the removal of pyroglutamic acid from the amino terminus of proteins using calf liver pyroglutamate amino peptidase.
    Podell DN; Abraham GN
    Biochem Biophys Res Commun; 1978 Mar; 81(1):176-85. PubMed ID: 26343
    [No Abstract]   [Full Text] [Related]  

  • 14. Amino acids are not un-charged (lipid-soluble) substances. Why we might as well forget pyroglutamate as an amino acid.
    Christensen HN
    Trends Pharmacol Sci; 1988 Dec; 9(12):430. PubMed ID: 3273495
    [No Abstract]   [Full Text] [Related]  

  • 15. Brain penetration of orally administered sodium pyroglutamate.
    Chanal JL; Audran M; Sicard MT; Briley M
    J Pharm Pharmacol; 1988 Aug; 40(8):584-5. PubMed ID: 2907018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular mechanisms of pidolate magnesium action and its neurotropic affects].
    Gromova OA; Torshin IY; Kalacheva AG; Fedotova LE; Rudakov KV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):96-103. PubMed ID: 28139633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic formation and utilization of 5-oxo-L-proline (L-pyroglutamate, L-pyrrolidone carboxylate).
    van der Werf P; Meister A
    Adv Enzymol Relat Areas Mol Biol; 1975; 43():519-56. PubMed ID: 1106127
    [No Abstract]   [Full Text] [Related]  

  • 18. Pyroglutamic aciduria (5-oxoprolinuria) without glutathione synthetase deficiency and with decreased pyroglutamate hydrolase activity.
    Roesel RA; Hommes FA; Samper L
    J Inherit Metab Dis; 1981; 4(2):89-90. PubMed ID: 6790862
    [No Abstract]   [Full Text] [Related]  

  • 19. Enzymatic conversion of D-glutamic acid to D-pyrrolidone carboxylic acid by mammalian tissues.
    MEISTER A; BUKENBERGER MW
    Nature; 1962 May; 194():557-9. PubMed ID: 14472271
    [No Abstract]   [Full Text] [Related]  

  • 20. [Synthesis and pharmacological activity of some carboxy pyrrolidinones and several derivatives (author's transl)].
    Robert J; Boucherle A
    Ann Pharm Fr; 1981; 39(4):337-46. PubMed ID: 7305244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.